TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Improvement in the appearance of lax skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: B-Line count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: changes in blood counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: changes in hepatic panel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in serum levels of HCV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of SUDEP or near-SUDEP
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants with undetectable HDV RNA or ≥ 2 log10 decrease in HDV RNA and ALT normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Intervention Usability Scale (IUS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Acceptability of Intervention Measure (AIM)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Implementation Appropriateness Measure (IAM)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Feasibility of Intervention Measure (FIM)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Shoulder ultrasound findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve from time zero to the last measurable concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amino-terminal propeptide of type I collagen (P1NP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: C-telopeptides of type I collagen (CTX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants with treatment related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Maternal exposure to RLYB212 as measured in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postoperative mortalities
Endpoint domain: Mortality/survival
Primary endpoint: Left lateral endurance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Right lateral endurance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of Ca-based renal stones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants With Treatment-emergent Adverse Events of Special Interest (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Chemoprevention failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Dose-normalized maximum observed plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-normalized area under the plasma concentration-time profile (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in physical fitness as assessed by the SPPB test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the 400-meter walk test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trial feasibility evaluation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change of plasma ferritin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of plasma hepcidin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of full blood counts concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of change in renin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Right ventricular-vascular coupling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Scale for the assessment and rating of ataxia (SARA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neurofilament plasma concentration (NfL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pulmonary vascular reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: New VTE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Degree of Disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Oral pharmacokinetics of caffeine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral pharmacokinetics of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral pharmacokinetics of TEV-56286
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in direct Low-density Lipoprotein Cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence of Treatment-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: completion of study procedures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: reliability evaluated through the number of device malfunctions
Endpoint domain: Adverse events/effects
Primary endpoint: Concentration of vitamin D in plasma/serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of calcium, potassium, and magnesium in human serum and urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Length from the vestibulum nasi to the posterior wall of the nasopharynx
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length from the vestibulum nasi to the mid-turbinate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Diaphragm capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction With Social Participation
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Hearing-Specific Health-Related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Frequency of Overactive Bladder Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: [Cu64]DOTATATE PET SUV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: MRI Size Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: GTR vs STR Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: ICU discharge status
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline of Physical Activity Questionnaire for Children (PAQ-C)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Serum Endothelial Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of TEAE of HP568
Endpoint domain: Adverse events/effects
Primary endpoint: 24 week clinical benefit rate (CBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with treatment and toxicity-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in RV-to-LV diameter ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of ISTH major bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of spinal cord injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Performance in activities of daily living and mobility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Humoral Immune Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Documentation quality of family conversations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of people engaging and being retained in substance use and HIV services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of people linking to other support services other than substance use or HIV services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Screen for Child Anxiety Related Emotional Disorders (SCARED)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in LDL profile between groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in very low density lipoprotein by spectral MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total sleep hours per night
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Executive function test (Stroop test), daily
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in executive function (EF)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Patients who Progressed to Severe Disease
Endpoint domain: Mortality/survival
Primary endpoint: Time Required for Patients on Treatment Arm to Progressed to Severe Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of axial neck pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge Assessment Scale for Dementia
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Knowledge Assessment Scale for Urinary Incontinence
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: change in hamstring range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: maintenance of change in hamstring range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: need for invasive or non-invasive ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of Depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of Anxiety Levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of Psychological distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Aortic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in intestinal permeability (% excretion of urinary sucralose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patient experience of frailty assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Visual Field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in LOC-E episode frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose area under curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Phase 2 Recommended Dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Gratitude Questionnaire 6-item (GQ-6)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: REI parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful thin catheter insertion at the first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Amplitude of sound pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour movement behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Boost in neutralizing antibody titers against Wuhan strain at Day 29
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immuno-inflammatory profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Color
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Concavity and convexity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: EPI prevalence
Endpoint domain: Mortality/survival
Primary endpoint: Success of duodenoscopy insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of vessel density (VD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elevated Total bilirubin (TcB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the ROC curve for hepatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability/Feasibility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in aortic valve calcification activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiac recurrence time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Push ups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sit ups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1 mile run
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 24-hour movement composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sulcular bleeding index (SBI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days of bleeding and spotting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Relative difference in LVOT VTI measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adherence to PrEP regimen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mucosal impedance pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of recruitment (enrollment rate)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Efficacy of single-dose HPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of prolonged thrombocytopenia (PT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of poor graft function (PGF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual rate of decline in FVC in mL (absolute)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Treatment Acceptability (Satisfaction assessed by Client Satisfaction Questionnaire-8)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients achieving sustained response to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: epidermis thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: size of vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: concentration of natural moisturizing factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Novel Eczema Biochemical Index (EBI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mechanical complications rates
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of hrHPV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Corneal Fluorescein Staining (CFS) scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Dry Eye Symptom scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-operative pain control on day 1 after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient recruitment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: protocol adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: follow-up completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in PCL-5 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lung CT scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Absence of emotional disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in beta cell responsivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean change in GLP-1 Area Under the Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Primary Graft Failure (GF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior patellofemoral pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of approached participants that are eligible for study participation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of participants that complete their final visit
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of participants that receive a sufficient number of coaching sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Safety of the EAS1 System
Endpoint domain: Adverse events/effects
Primary endpoint: The Arabic Version Of Neck Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Individual Cortisol Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cancer status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants with Grade >= 2 Treatment-Emergent Corneal Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximal Concentration (Cmax) of Mirvetuximab Soravtansine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rasch-Based MAL-18
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Chedoke Arm and Hand Activity Inventory (CAHAI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Duröz Hand Index (DHI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of DFUs healed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean (GM) of SARS-CoV-2 neutralizing titers in all participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Naming of Trained Words
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary fibrotic biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delirium risk prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge Measurement Survey for Grandchild Care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: State and Trait Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pharis Self-Confidence Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Photographic Shoulder Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Study Retention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 12-Month Intracranial Progression-Free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Changes in binge eating symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in objective binge eating episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified Barthel index (mBI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of screen-detected asymptomatic brain metastasis
Endpoint domain: Mortality/survival
Primary endpoint: Mean interstitial glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time spent at each glucose range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum ocrelizumab area under the concentration-time curve (AUCW1-12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes